Company News      Oct. 2006-2007 West Africa       JNI Medical Côte d'Ivoire, provides one million Malaria, HIV and TB tests for screening and prevention in  Ivory Coat, Burkina Faso, Niger, Mali, Senegal,Benin, Togo, Chad, Cameroon, Sierra Leone, Gambia, Ghana, Guinea, and Mauritania 2006-2007   JNI Medical Côte d'Ivoire, provided one million Meningococcal meningitis A+C vaccine to  Ivory Coat, Burkina Faso, Niger, Mali, Senegal, Benin, Togo, Chad, Cameroon, Sierra Leone, Gambia, Ghana, Guinea, Mauritania and South Africa 2006-2007   Jan/24/2007 South America     JNI Medical USA, to screen 2.5 children under the age of 18 for the presence of Tuberculosis in Bolivia in an association of Mano a Mano Medical Services     Vaccine Development      Vaccine for Stoke      Genital Herpes      Bovine Viral diarrhea virus      Hepatitis B DNA Vaccine      Hepatitis C DNA Vaccine     Meningococcal serotype B      Tuberculosis      HIV vaccine initiative      Herpes Simples Virus     Member of Global Org. Clinton Global Health  GBC   Global Health Council   International AID+TRADE     Countries/Regions E-mail JN-AFRICACôte d'IvoireBurkina FasoNigerMaliTogoSierra LeoneSenegalNigeriaSenegalSouth AfricaMauritaniaLiberiaGuinea-BissauGuineaGhanaGambiaCape VerdeBeninKenyaTanzaniaTanzaniaEthiopiaUgandaSouth AfricaMozambiqueMadagascarMalawiZambiaZimbabweSudan   Home  ::  Research  ::  cGMP  ::  Scientific-Personnel :: Contact us ::   Production of Low-Cost Vaccines and Diagnostics   Objective: To eliminate preventable infectious diseases through the development and production of low-cost vaccines and rapid diagnostic test kits.   Strategies: 1. The manufacture of a meningococcal A, C, Y, W-135 vaccine. 2. The development and production of a meningococcal A, C, Y, W-135 conjugate vaccine. 3. The sale and distribution of rapid test kits for malaria, TB, and HIV. 4. The development and clinical testing of a stroke and epilepsy vaccine. 5. The development and clinical testing of a Hepatitis C vaccine. 6. The construction of a manufacturing and vial facility near JN's current headquarters. This project is designed to address the growing need for biological products in developing countries, especially Africa. There is an increasing demand for meningococcal vaccines in developed countries, and unfortunately this demand has created a shortage throughout Africa. This is where the private sector and NGO must assure a major role. JN, with the help of charitable organizations and its worldwide business partners, will be able to provide low cost effective vaccines to prevent infectious diseases.   Geographic Scope:    Africa, South East Asia, South America   Milestones and Key Actions: AFRICA:     Vaccine Division : Initial manufacture of 1-2 million doses of Meningococcal A, C, Y, W-135 polysaccharide vaccine completed at the end of 2007. Utilizing its newly completed facilities in Omaha, NE, JN hopes to complete the initial large-scale production of 2 million doses of its Meningococcal A, C, Y, W-135 polysaccharide vaccine. Clinical Research Trials: Clinical trials for Meningococcal A, C, Y, W-135 DT Conjugate vaccine Clinical trials going on in North Côte d'Ivoire and this meningococcal conjugate vaccine developed by JN for sale primarily in African children.  Diagnostic Division : Supply of 2 million Malaria, Tuberculosis, and HIV 1/2 rapid diagnostic test kits to West Africa: February 2007. JN has had a long-standing relationship with contract manufacture facilities in the US, which enables us large-scale production capabilities for rapid diagnostic tests for Malaria, TB, and HIV. It is our goal to supply two million diagnostic tests for Malaria, TB, and HIV to West Africa in 2007. SOUTH AMERICA:   JNI Medical USA, to screen 2.5 children under the age of 18 for the presence of Tuberculosis in Bolivia in an association of Mano a Mano Medical Services, Bolivia. Miles stone achievement:  JNI Medical Côte d'Ivoire, provides 1 million Malaria, HIV and TB tests for screening and prevention in  Ivory Coat, Burkina Faso, Niger, Mali, Senegal, Benin, Togo, Chad, Cameroon, Sierra Leone, Gambia, Ghana, Guinea and Mauritania 2006-2007. JNI Medical Côte d'Ivoire, providing and stocked one million Meningococcal meningitis A+C vaccine (a third party vaccine) to  Ivory Coat, Burkina Faso, Niger, Mali, Senegal, Benin, Togo, Chad, Cameroon, Sierra Leone, Gambia, Ghana, Guinea, and Mauritania 2006-2007 Partnership Opportunities: JN Medical Corporation would be willing to consider partnership. Our company's outstanding needs are primarily financial, manufacture and research however we would welcome any partnership which would allow us to provide our products to global health organizations and foreign governments or affiliated organizations.                                                                Global Health Contribution